Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Atopic Dermatitis | Emerging Therapies | Eucrisa (crisaborole) | US | Wave 3 | 2018

Login to access report north_east
Contact sales account_box

Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data collected at 1, 6, and 12 months post-commercial launch from surveys of U.S. dermatologists. Along with awareness of, sources of familiarity with, and perceptions related to Eucrisa, the research assesses trial, adoption, and usage, including anticipated future trends, of Eucrisa. We also explore Pfizer’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.

What you will learn in this content:

  • What is U.S. dermatologists’ awareness of and familiarity with Eucrisa, and what are their perceptions of this product?
  • Among prescribers, for which patients are they prescribing Eucrisa, what are the reasons for prescribing, and how satisfied are they with Eucrisa?
  • What are the promotional messages and activities that Pfizer is employing in support of the Eucrisa launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Eucrisa tracking compared with other recent product launches in the AD market?

Methodology: ~75 U.S. dermatologists completed a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.

Key drugs: Eucrisa

Key companies: Pfizer

Related reports: Atopic Dermatitis | Disease Landscape and Forecast | US/EU/Japan, Atopic Dermatitis | Unmet Need | US/EU, Atopic Dermatitis | Access & Reimbursement | US, Atopic Dermatitis | Access and Reimbursement | EU5, Atopic Dermatitis | Current Treatment | EU5

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…
north_east
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
north_east
Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
north_east
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east